Lamotrigine in psychiatric disorders

Journal of Clinical Psychiatry

Volumn 74, Issue 7, 2013, Pages 675-684

  Reid, Jennifer G ^a   Gitlin, Michael J ^a   Altshuler, Lori L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DESIPRAMINE; FLUOXETINE; GABAPENTIN; INOSITOL; LAMOTRIGINE; LITHIUM; OLANZAPINE; PAROXETINE; PLACEBO; RISPERIDONE; SERTRALINE; VALPROIC ACID;

ANXIETY DISORDER; APPETITE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BLISTER; BORDERLINE STATE; CASE STUDY; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DRESS SYNDROME; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; ERYTHRODERMA; HUMAN; LEUKOPENIA; LYMPHADENOPATHY; MAINTENANCE THERAPY; MAJOR DEPRESSION; MENTAL DISEASE; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHRITIS; NEUROTOXICITY; OPEN STUDY; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SKIN SCAR; SKIN TOXICITY; SOMNOLENCE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; URTICARIA; WEIGHT GAIN; XEROSTOMIA;

EID: 84881014605     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12r08046     Document Type: Review

References (62)

1. Smith D, Baker G, Davies G, et al. Outcomes of add on treatment with lamotrigine in partial epilepsy. Epilepsia. 1993;34(2):312-322.
2. Calabrese JR, Bowden CL, Sachs G, et al; Lamictal 605-Study Group. A placebo controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013-1024.
3. Bowden CL, Calabrese JR, Sachs G, et al; Lamictal 606-Study Group. A placebo controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400.
4. Lamictal (lamotrigine) [package insert]. Research Triangle Park, NC: GlaxoSmithKline 2011.
5. Thomas SP, Nandhra HS, Jayaraman A. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD).J Ment Health. 2010;19(2):168-175.
6. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol. 2001;15(6):405-417.
7. Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception. 2011;83(1):16-29.
8. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia. 2000;41(6): 709-713.
9. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure. 1998;7(2):163-165.
10. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 1999;40(8) :1141-1146.
11. Besag FMC, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 1998;39(2): 183-187.
12. Amann B, Born C, Crespo JM, et al. Lamotrigine: when and where does it act in affective disorders? a systematic review. J Psychopharmacol. 2011;25(10): 1289-1294.
13. Calabrese JR, Bowden CL, Sachs GS, et al. A double blind placebo controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602-Study Group. J Clin Psychiatry. 1999;60(2):79-88.
14. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double blind, placebo controlled clinical trials. Bipolar Disord. 2008;10(2):323-333.
15. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta analysis and meta regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4-9.
16. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607-614.
17. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67(7):1025-1033.
18. Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009;12(6):773-782.
19. Schaffer A, Zuker P, Levitt A. Randomized, double blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression.J Affect Disord. 2006;96(1-2):95-99.
20. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment resistant bipolar depression: a STEP BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163(2):210-216.
21. van der Loos ML, Mulder PG, Hartong EG, et al; LamLit Study Group. Efficacy and safety of lamotrigine as add on treatment to lithium in bipolar depression: a multicenter, double blind, placebo controlled trial. J Clin Psychiatry. 2009;70(2):223-231.
22. van der Loos ML, Mulder P, Hartong EG, et al; LamLit Study Group. Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand. 2010;122(3):246-254.
23. van der Loos ML, Mulder PG, Hartong EG, et al; LamLit Study Group. Long term outcome of bipolar depressed patients receiving lamotrigine as add on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo controlled trial with a novel design. Bipolar Disord. 2011;13(1):111-117.
24. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225-255.
25. Sharma V, Khan M, Corpse C. Role of lamotrigine in the management of treatment resistant bipolar II depression: a chart review. J Affect Disord. 2008;111(1):100-105.
26. Jung I, Lee M, Kang B, et al. Lamotrigine treatment for patients with bipolar II disorder: retrospective report of 30-cases. Bipolar Disord. 2008;10(suppl 1): 45-46.
27. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2-placebo controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004;65(3):432-441.
28. Licht RW, Nielsen JN, Gram LF, et al. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice: The 6th trial of the Danish University Antidepressant Group (DUAG 6). Bipolar Disord. 2010;12(5): 483-493.
29. Calabrese JR, Suppes T, Bowden CL, et al. A double blind, placebo controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder. Lamictal 614-Study Group. J Clin Psychiatry. 2000;61(1-1):841-850.
30. Goldberg JF, Bowden CL, Calabrese JR, et al. Six month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder. Biol Psychiatry. 2008;63(1):125-130.
31. Goldberg JF, Calabrese JR, Saville BR, et al. Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. J Clin Psychiatry. 2009;70(9): 1273-1280.
32. Normann C, Hummel B, Scharer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: a placebo controlled, double blind study. J Clin Psychiatry. 2002;63(4):337-344.
33. Barbosa L, Berk M, Vorster M. A double blind, randomized, placebo controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003;64(4):403-407.
34. Barbee JG, Thompson TR, Jamhour NJ, et al. A double blind placebo controlled trial of lamotrigine as an antidepressant augmentation agent in treatment refractory unipolar depression. J Cliii Psychiatry. 201-1;72-(10): 1405-1412.
35. Schindler F, Anghelescu I. The LILA Study: an observational study comparing the efficacy of lithium vs lamotrigine as an augmentation strategy for treatment resistant depression (TRD). Abstract 140. Proceedings from the 59th Annual Meeting of the Society of the Society of Biological Psychiatry (SOBP). New York, NY; April29-May 1,2004.
36. Schindler F, Anghelescu LG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open label study. Int Clin Psychopharmacol. 2007;22(3): 179-182.
37. Rybakowski J, Tuszewska M. Lithium or lamotrigine augmentation in treatment resistant depression. Int Clin Psychopharmacol. 2006;9(suppl 1);s232.
38. Ivkovié M, Damjanovié A, Jovanovié A, et al. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment resistant depression: efficacy and tolerability. Psychiatr Danub. 2009;21-(2): 187-193.
39. Baloescu A, Grigorescu G, Gheorghe MD. LTG in the treatment of resistant depression. Abstract 93. 14th Association of European Psychiatrists Congress; March 4-8, 2006; Nice, France.
40. Dimellis D, Kouniakis E Lamotrigine as an adjunctive agent for treatment resistant depressed patients already treated with sertraline an open label study. Int J Neuropsychopharmacol. 2004;2:5162.
41. Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress Anxiety. 2006;23(8):485-488.
42. Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment resistant depression. J Clin Psychiatry. 2002;63(8):737-741.
43. Rocha FL, Hara C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol. 2003;18(2):97-99.
44. Gutierrez RL, McKercher RM, Galea J, et al. Lamotrigine augmentation strategy for patients with treatment resistant depression. CNS Spectr. 2005; 10(10):800-805.
45. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline patients: a randomized, double blind, placebo controlled study. J Psychopharmacol. 2005;19(3):287-291.
46. Leiberich P, Nickel MK, Tritt K, et al. Lamotrigine treatment of aggression in female borderline patients, pt 2: an 18-month follow up. J Psychopharmacol. 2008;22(7):805-808.
47. Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24(5):270-275.
48. Weinstein W, Jamison KL. Retrospective case review of lamotrigine use for affective instability of borderline personality disorder. C'NS Spectr. 2007; 12(3):207-210.
49. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM IV major mood disorder. J Affect Disord. 1998;51(3):333-343.
50. Preston GA, Marchant BK, Reimherr FW, et al. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord. 2004;79(1-3):297-303.
51. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 200-1;158(9): 1367-1377.
52. Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev. 2006;18(4):CD005962.
53. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine resistant schizophrenia: a systematic review and meta analysis. SchizophrRes. 2009;109(1-3):1O 14.
54. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45(9):1226-1229.
55. Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re uptake inhibitors in obsessive compulsive disorder. AustNzJ Psychiatry. 2000;34(3):527-528.
56. Uzun O. Lamotrigine as an augmentation agent in treatment resistant obsessive compulsive disorder: a case report. J Psychopharinacol. 2010;24(3):425-427.
57. Bisol LW, Lara DR. Improvement of obsessive compulsive disorder with divalproex and lamotrigine in two patients with bipolar II disorder. Pharniacopsychiatry. 2009;42 (1)37-39.
58. Masdrakis VG, Papadimitriou GN, Oulis P. Lamotrigine administration in panic disorder with agoraphobia. Clin Neuropharinacol. 2010;33(3): 126-128.
59. Seo HJ, Chiesa A, Lee SJ, et al. Safety and tolerability of lamotrigine: results from 12-placebo controlled clinical trials and clinical implications. Clin Neuropharniacol. 2011;34(1):39-47.
60. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002;63(11):1012-1019.
61. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40(7):985-991.
62. Lamictal Advisory Board Briefing Document. Glaxo Wellcome; 1997.